Vabysmo

VABYSMO represents the first major MOA development in the treatment of retinal vascular diseases such as nAMD and DME in over 15 years. As the first-and-only dual-pathway inhibitor, it sets a new standard for patients and the HCPs that treat them. We needed to convince HCPs of the true innovation VABYSMO delivers — The power of TWO.